Mainland Europe is often said to be the problem child in the continent’s academic family when it comes to technology transfer, especially compared with the UK’s successes. And with dozens of spinouts being churned out by the golden triangle of London, Oxford and Cambridge alone, it is easy to assign some truth to such a statement.
Ambys Medicines has raised $60m in a series A round backed by Takeda and signed a strategic partnership agreement with the corporate worth $80m.
Isis Innovation's Rakesh Roshan investigates the looming age of quantum computing.
GUV's list of hot spin-outs to watch in 2015.
A review of our latest event, the GUV Summit 2014.